Safety, Efficacy and Patient Acceptability of the Contraceptive and Non-Contraceptive Uses of the LNG-IUS

Intrauterine devices (IUDs) provide highly effective, long-term, safe, reversible contraception, and are the most widely used reversible contraceptive method worldwide. The levonorgestrel-releasing intrauterine system (LNG-IUS) is a T-shaped IUD with a steroid reservoir containing 52 mg of levonorgestrel that is released at an initial rate of 20 μg daily. It is highly effective, with a typical-use first year pregnancy rate of 0.1% – similar to surgical tubal occlusion. It is approved for 5 years of contraceptive use, and there is evidence that it can be effective for up to 7 years of continuous use. After removal, there is rapid return to fertility, with 1-year life-table pregnancy rates of 89 per 100 for women less than 30 years of age. Most users experience a dramatic reduction in menstrual bleeding, and about 15% to 20% of women become amenorrheic 1 year after insertion. The device’s strong local effects on the endometrium benefit women with various benign gynecological conditions such as menorrhagia, dysmenorrhea, leiomyomata, adenomyosis, and endometriosis. There is also evidence to support its role in endometrial protection during postmenopausal estrogen replacement therapy, and in the treatment of endometrial hyperplasia.

[1]  A. Lethaby,et al.  Surgery versus medical therapy for heavy menstrual bleeding. , 2016, The Cochrane database of systematic reviews.

[2]  J. Trussell Medical eligibility criteria for contraceptive use , 2011 .

[3]  D. Creedon,et al.  Term pregnancy with intraperitoneal levonorgestrel intrauterine system: a case report and review of the literature. , 2009, Contraception.

[4]  D. Lu,et al.  The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. , 2009, Contraception.

[5]  C. Mangioni,et al.  Fertility‐sparing treatment in young women with endometrial cancer or atypical complex hyperplasia: a prospective single‐institution experience of 21 cases , 2009, BJOG : an international journal of obstetrics and gynaecology.

[6]  A. Ørbo,et al.  Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only. , 2008, Gynecologic oncology.

[7]  T. J. Clark,et al.  The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia--a long-term follow-up study. , 2008, European journal of obstetrics, gynecology, and reproductive biology.

[8]  L. Dennis,et al.  Meta-analysis of intrauterine device use and risk of endometrial cancer. , 2008, Annals of epidemiology.

[9]  J. Jensen,et al.  Subject and clinician experience with the levonorgestrel-releasing intrauterine system. , 2008, Contraception.

[10]  O. Stephansson,et al.  Cervical priming with sublingual misoprostol prior to insertion of an intrauterine device in nulliparous women: a randomized controlled trial. , 2007, Human reproduction.

[11]  L. Bahamondes,et al.  Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging. , 2007, Contraception.

[12]  J. Guest,et al.  Cost-utility of levonorgestrel intrauterine system compared with hysterectomy and second generation endometrial ablative techniques in managing patients with menorrhagia in the UK , 2007, Current medical research and opinion.

[13]  A. Kaunitz Progestin-releasing intrauterine systems and leiomyoma. , 2007, Contraception.

[14]  P. Castaño Use of intrauterine devices and systems by HIV-infected women. , 2007, Contraception.

[15]  E. Espey,et al.  Intrauterine contraception: the pendulum swings back. , 2007, Obstetrics and gynecology clinics of North America.

[16]  M. Khamashta,et al.  Treatment of menorrhagia associated with oral anticoagulation: efficacy and safety of the levonorgestrel releasing intrauterine device (Mirena coil) , 2006, Lupus.

[17]  J. Jensen,et al.  A US multicenter open-label trial with the levonorgestrel-releasing intrauterine system clinical and device-related experience , 2006 .

[18]  Pai-Lien Chen,et al.  Pain from copper intrauterine device insertion: randomized trial of prophylactic ibuprofen. , 2006, American journal of obstetrics and gynecology.

[19]  A. Ørbo,et al.  Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia. , 2006, Gynecologic oncology.

[20]  C. Farquhar,et al.  A randomised trial comparing the levonorgestrel intrauterine system and thermal balloon ablation for heavy menstrual bleeding , 2006, BJOG : an international journal of obstetrics and gynaecology.

[21]  R. Salem New attention to the IUD: expanding women's contraceptive options to meet their needs. , 2006, Population reports. Series B, Intrauterine devices.

[22]  M. Koskenvuo,et al.  Use of the Levonorgestrel-Releasing Intrauterine System and Breast Cancer , 2005, Obstetrics and gynecology.

[23]  D. Barlow,et al.  Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women. , 2005, Human reproduction.

[24]  R. Ferriani,et al.  Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. , 2005, Human reproduction.

[25]  F. Lockhat,et al.  The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up. , 2005, Human reproduction.

[26]  R. Woolas,et al.  Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature. , 2005, Gynecologic oncology.

[27]  F. Lockhat,et al.  The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up , 2005 .

[28]  S. Soysal,et al.  The Efficacy of Levonorgestrel-Releasing Intrauterine Device in Selected Cases of Myoma-Related Menorrhagia: A Prospective Controlled Trial , 2005, Gynecologic and Obstetric Investigation.

[29]  S. Deitcher,et al.  Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. , 2004, Archives of internal medicine.

[30]  J. Schlesselman,et al.  Safety concerns and health benefits associated with oral contraception. , 2004, American journal of obstetrics and gynecology.

[31]  A. Aktulay,et al.  Clinical outcomes of early postplacental insertion of intrauterine contraceptive devices. , 2004, Contraception.

[32]  S. Grénman,et al.  Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. , 2004, JAMA.

[33]  P. Vercellini,et al.  Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. , 2004, Fertility and sterility.

[34]  H. Maia,et al.  Insertion of mirena after endometrial resection in patients with adenomyosis. , 2003, The Journal of the American Association of Gynecologic Laparoscopists.

[35]  L. Bahamondes,et al.  Levonorgestrel‐releasing intrauterine system (Mirena®) as a therapy for endometrial hyperplasia and carcinoma , 2003, Acta obstetricia et gynecologica Scandinavica.

[36]  M. Dhont,et al.  Treatment of nonatypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system. , 2003, American journal of obstetrics and gynecology.

[37]  M. Chen-Mok,et al.  Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas. , 2003, Fertility and sterility.

[38]  J. Otero-Flores,et al.  A comparative randomized study of three different IUDs in nulliparous Mexican women. , 2003, Contraception.

[39]  B. Xiao,et al.  Therapeutic effects of the levonorgestrel-releasing intrauterine system in the treatment of idiopathic menorrhagia. , 2003, Fertility and sterility.

[40]  S. Soysal,et al.  A randomized controlled trial of levonorgestrel releasing IUD and thermal balloon ablation in the treatment of menorrhagia. , 2002, Zentralblatt fur Gynakologie.

[41]  F. Montz,et al.  Intrauterine progesterone treatment of early endometrial cancer. , 2002, American journal of obstetrics and gynecology.

[42]  D. Grimes,et al.  Noncontraceptive Health Benefits of Intrauterine Devices: A Systematic Review , 2002, Obstetrical & gynecological survey.

[43]  L. Bahamondes,et al.  Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. , 2002, Contraception.

[44]  I. Rauramo,et al.  A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. , 2001, Fertility and sterility.

[45]  A. Zeleniuch‐Jacquotte,et al.  Role of Exogenous and Endogenous Hormones in Endometrial Cancer , 2001, Annals of the New York Academy of Sciences.

[46]  D. Taylor,et al.  Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. , 2001, The New England journal of medicine.

[47]  C. Morrison,et al.  Is the intrauterine device appropriate contraception for HIV‐1‐infected women? , 2001 .

[48]  I. Sivin,et al.  Immediate postabortal contraception with the levonorgestrel intrauterine device, Norplant, and traditional methods. , 2001, Contraception.

[49]  R. Raffaelli,et al.  Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis. , 2001, Fertility and sterility.

[50]  J. Shelton Risk of clinical pelvic inflammatory disease attributable to an intrauterine device , 2001, The Lancet.

[51]  C. Morrison,et al.  Is the intrauterine device appropriate contraception for HIV‐infected women? , 2000, BJOG : an international journal of obstetrics and gynaecology.

[52]  F. al-Azzawi,et al.  Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial , 2000, The Lancet.

[53]  D. Grimes Intrauterine device and upper-genital-tract infection , 2000, The Lancet.

[54]  L. Bahamondes,et al.  Acceptability and performance of the levonorgestrel-releasing intrauterine system (Mirena) in Campinas, Brazil. , 2000, Contraception.

[55]  R. Luoto,et al.  Length of use and symptoms associated with premature removal of the levonorgestrel intrauterine system: a nation‐wide study of 17,360 users , 2000, BJOG : an international journal of obstetrics and gynaecology.

[56]  S. Logan,et al.  Hormonally impregnated intrauterine systems (IUSs), versus other forms of reversible contraceptives as effective methods of preventing pregnancy. , 2000, The Cochrane database of systematic reviews.

[57]  Kuldip Singh,et al.  Medical treatment of a grossly enlarged adenomyotic uterus with the levonorgestrel-releasing intrauterine system. , 1999, Contraception.

[58]  K. Schulz,et al.  Prophylactic antibiotics for intrauterine device insertion: a metaanalysis of the randomized controlled trials. , 1999, Contraception.

[59]  V. Odlind,et al.  Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use. , 1999, Acta obstetricia et gynecologica Scandinavica.

[60]  A. Charlett,et al.  The rate of diagnosis and demography of pelvic inflammatory disease in general practice: England and Wales , 1999, International journal of STD & AIDS.

[61]  A. Kauppila,et al.  The levonorgestrel intrauterine system in menopausal hormone replacement therapy: five-year experience. , 1999, Fertility and sterility.

[62]  I. Cameron,et al.  Randomised comparative trial of the intrauterine system and norethisterone levonor gestrel for treatment of idiopathic menorrhagia , 1998 .

[63]  I. Milsom,et al.  Perforations with intrauterine devices. Report from a Swedish survey. , 1998, Contraception.

[64]  H. Koistinen,et al.  Levonorgestrel-releasing intrauterine device-wearing women express contraceptive glycodelin A in endometrium during midcycle: another contraceptive mechanism? , 1997, Human reproduction.

[65]  S. Suhonen,et al.  Three‐year follow‐up of the use of a levonorgestrel‐releasing intrauterine system in hormone replacement therapy , 1997, Acta obstetricia et gynecologica Scandinavica.

[66]  J. Forrest U.S. women's perceptions of and attitudes about the IUD. , 1996, Obstetrical & gynecological survey.

[67]  C. Bardin,et al.  Mechanisms of action of intrauterine devices. , 1996, Obstetrical & gynecological survey.

[68]  J. Suvisaari,et al.  Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of a copper IUD or a levonorgestrel-releasing intrauterine system. , 1996, Contraception.

[69]  L. Mattsson,et al.  Intrauterine or oral administration of levonorgestrel in combination with estradiol to perimenopausal women--effects on lipid metabolism during 12 months of treatment. , 1996, International journal of fertility and menopausal studies.

[70]  K. Treiman,et al.  IUDs--an update. , 1995, Population reports. Series B, Intrauterine devices.

[71]  E. Coutinho,et al.  Ovarian function after seven years' use of a levonorgestrel IUD , 1995, Advances in contraception : the official journal of the Society for the Advancement of Contraception.

[72]  J. Annus,et al.  Tubal Infertility: Serologic Relationship to Past Chlamydial and Gonococcal Infection , 1995 .

[73]  S. Suhonen,et al.  Sustained-release estradiol implants and a levonorgestrel-releasing intrauterine device in hormone replacement therapy. , 1995, American journal of obstetrics and gynecology.

[74]  E. Searle,et al.  Long acting methods of contraception , 1994, BMJ.

[75]  T. Bourne,et al.  Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial , 1994, The Lancet.

[76]  J. Willem,et al.  Risk of endometrial cancer after tamoxifen treatment of breast cancer , 1994, The Lancet.

[77]  A. Faúndes,et al.  Evaluation of the clinical performance of a levonorgestrel-releasing IUD, up to seven years of use, in Campinas, Brazil. , 1993, Contraception.

[78]  G. Rybo,et al.  Return to fertility after removal of a levonorgestrel-releasing intrauterine device and Nova-T. , 1992, Contraception.

[79]  S. Mumford,et al.  Was the Dalkon Shield a safe and effective intrauterine device? The conflict between case-control and clinical trial study findings. , 1992, Fertility and sterility.

[80]  D. Mishell,et al.  Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices. , 1992, American journal of obstetrics and gynecology.

[81]  T. Farley,et al.  Intrauterine devices and pelvic inflammatory disease: an international perspective , 1992, The Lancet.

[82]  D. Mishell,et al.  Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the Copper T380 Ag IUDS. , 1991, Contraception.

[83]  I. Sivin Dose- and age-dependent ectopic pregnancy risks with intrauterine contraception. , 1991, Obstetrics and gynecology.

[84]  I. Milsom,et al.  A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. , 1991, American journal of obstetrics and gynecology.

[85]  V. Odlind,et al.  Ovarian function during use of a levonorgestrel-releasing IUD. , 1990, Contraception.

[86]  P. Lähteenmäki,et al.  The levonorgestrel-releasing intrauterine device. , 1990, Advances in contraceptive delivery systems : CDS.

[87]  B. Xiao,et al.  Pharmacokinetic and pharmacodynamic studies of levonorgestrel-releasing intrauterine device. , 1990, Contraception.

[88]  I. Sivin IUDs are contraceptives, not abortifacients: a comment on research and belief. , 1989, Studies in family planning.

[89]  S. Wu,et al.  The effect of intrauterine devices, the stainless steel ring, the copper T220, and releasing levonorgestrel, on the bleeding profile and the morphological structure of the human endometrium--a comparative study of three IUDs. A morphometric study of 96 cases. , 1989, Contraception.

[90]  J. Annegers,et al.  Risk factors for ectopic pregnancy. A population-based study. , 1988 .

[91]  N. Nielsen,et al.  Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of a European multicenter study. , 1987, Contraception.

[92]  H. Croxatto,et al.  Long-term follow-up of women treated with NORPLANTR implants* , 1987 .

[93]  E. Cittadini,et al.  Treatment of endometrial hyperplasia with levonorgestrel releasing intrauterine devices. , 1987, Acta Europaea fertilitatis.

[94]  D. Mishell,et al.  Recovery of fertility after use of the levonorgestrel 20 mcg/d or Copper T 380 Ag intrauterine device. , 1986, Contraception.

[95]  T. Luukkainen,et al.  Endometrial Morphology During Long‐Term Use of Levonorgestrel‐Releasing Intrauterine Devices , 1986, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[96]  P. Lahteenmaki,et al.  Sustained intrauterine release of levonorgestrel over five years. , 1986, Fertility and sterility.

[97]  T. Luukkainen,et al.  TISSUE CONCENTRATIONS OF LEVONORGESTREL IN WOMEN USING A LEVONORGESTREL‐RELEASING IUD , 1982, Clinical endocrinology.

[98]  G. Söderberg,et al.  Influence of an intrauterine device on the course of an acute salpingitis. , 1981, Contraception.

[99]  L Weström,et al.  Incidence, prevalence, and trends of acute pelvic inflammatory disease and its consequences in industrialized countries. , 1980, American journal of obstetrics and gynecology.

[100]  T. Luukkainen,et al.  Plasma concentrations of levonorgestrel as a function of the release rate of levonorgestrel from medicated intra-uterine devices. , 1980, Acta endocrinologica.

[101]  R. Rochat,et al.  Intrauterine Device Termination Rates and the Menstrual Cycle Day of Insertion , 1980, Obstetrics and gynecology.

[102]  A. Cervantes,et al.  [Mechanism of action of intrauterine devices]. , 1979, Ginecologia y obstetricia de Mexico.

[103]  J. Paavonen,et al.  Experience with the levonorgestrel-releasing intrauterine system among HIV-infected women. , 2007, Contraception.

[104]  C. Cwiak,et al.  A pilot clinical trial of ultrasound-guided postplacental insertion of a levonorgestrel intrauterine device. , 2007, Contraception.

[105]  Germán L. Rosano,et al.  Doses of levonorgestrel comparable to that delivered by the levonorgestrel-releasing intrauterine system can modify the in vitro expression of zona binding sites of human spermatozoa. , 2006, Contraception.

[106]  A. Lethaby,et al.  Surgery versus medical therapy for heavy menstrual bleeding. , 2006, Cochrane Database of Systematic Reviews.

[107]  M. Koskenvuo,et al.  Pregnancy during the use of levonorgestrel intrauterine system. , 2004, American journal of obstetrics and gynecology.

[108]  K. Wellings,et al.  Amenorrhea associated with contraception-an international study on acceptability. , 2003, Contraception.

[109]  L. Bahamondes,et al.  Users’ Perspectives on Bleeding Patterns after Two Years of Levonorgestrel-Releasing Intrauterine System Use , 2002, Drugs in R&D.

[110]  Krishnan Sharma,et al.  UNITED NATIONS DEPARTMENT OF ECONOMIC AND SOCIAL AFFAIRS , 1999 .

[111]  I. Cameron,et al.  Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. , 1998, British journal of obstetrics and gynaecology.

[112]  T. Raudaskoski,et al.  Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses. , 1995, American journal of obstetrics and gynecology.

[113]  V. Odlind,et al.  Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. , 1994, Contraception.

[114]  I. Sivin,et al.  Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR). , 1994, Fertility and sterility.

[115]  I. Sivin Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years' comparative experience of levonorgestrel- and copper-releasing intrauterine devices. , 1991, Obstetrics and gynecology.

[116]  H. Croxatto,et al.  [Long-term follow-up of women treated with contraceptive implants of levonorgestrel Norplant]. , 1989, Revista chilena de obstetricia y ginecologia.

[117]  H. Croxatto,et al.  Long-term follow-up of women treated with Norplant implants. , 1987, Contraception.

[118]  T. Luukkainen,et al.  Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing intrauterine device. , 1984, Fertility and sterility.

[119]  IUD insertion following termination of pregnancy: a clinical trial of the TCu 220C, Lippes loop D, and copper 7. , 1983, Studies in family planning.